Cabergoline reduces post-loss lactation symptoms

A single 1 mg dose of cabergoline reduced breast symptoms after abortion or pregnancy loss at 16–20 weeks.
*Double-blind randomized controlled trial; Oxford evidence Level 1b.

Citation

Henkel A, Cahill EP, Chavez S, et al. Cabergoline for Lactation Inhibition After Early Second-Trimester Abortion or Pregnancy Loss: A Randomized Controlled Trial. Obstet Gynecol. 2026;147:277-284. doi:10.1097/AOG.0000000000006137

Background

Breast pain, engorgement, and milk leakage can occur after abortion or pregnancy loss beginning in the second trimester and may worsen distress. Cabergoline has been used to suppress milk production later in pregnancy, but evidence was limited at 16–20 weeks.

Patients

Sixty-six English- or Spanish-speaking pregnant adults undergoing abortion or management of fetal death at 16 0/7–19 6/7 weeks. Exclusions included current breastfeeding, prior mastectomy, dopamine-related drug use, or cabergoline contraindication.

Intervention

Cabergoline 1 mg once, within 4 hours of uterine evacuation or fetal expulsion, plus usual supportive advice.

Control

Placebo plus usual supportive advice, including support bra and ice packs as needed.

Outcome

Primary outcome: any breast symptom on day 4, using the Bristol Breast Symptoms Inventory: engorgement, leakage, tenderness, and need for pain relief (each 1–4; 1 means absent). Bother was rated 0–6.

Follow-up Period

14 days.

Results

Outcome Cabergoline Placebo Clinical effect
Any breast symptoms, day 4 (primary) 50.0% 88.2% Number needed to treat: 3
Engorgement, day 4 25.0% 70.6% Absolute reduction: 45.6%
Breast tenderness, day 4 40.6% 81.8% Absolute reduction: 41.2%
Need for pain medicine, day 4 6.3% 29.4% Absolute reduction: 23.1%
Significant bother, day 7 0% 20.6% Number needed to treat: 5
Nausea or vomiting 34.4% 5.9% Number needed to harm: 4

Analysis was modified intention-to-treat. The trial tested superiority. Placebo was not an active treatment; both groups received supportive measures.

Limitations

Small sample size limited side-effect assessment. Outcomes were self-reported, and expectation bias may remain despite blinding. One-third of approached patients declined participation.

Funding

Stanford Dunlevie Maternal-Fetal Medicine Center; no reported conflicts.

Clinical Application

Offer cabergoline after abortion or pregnancy loss starting at 16 weeks, while counseling about common mild side effects, especially nausea.